Influence of local recurrence on survival in patients with rectal cancer
MetadataShow full item record
Background: Recent trials on rectal cancer have demonstrated significant improvements in local recurrence without improvements in overall survival. The aim of this paper was to define the influence of local recurrence on survival in a prospective series of patients who underwent R0 or R1 resections for rectal cancer. Methods: Patients presenting with rectal cancer from 1996 to 2012 were prospectively audited. The study included patients who underwent an R0 or R1 resection. Local recurrence was defined as cancer regrowth detected in the pelvis regardless of whether or not new metastases were found elsewhere. Kaplan–Meier curves, smoothed hazard functions and Cox models using both time since diagnosis and age as the time scale were used to define the influence of local recurrence on overall survival. Results: The study involved 483 patients, of mean age 66 years (standard deviation = 13) and a median follow-up of 5.2 years. The results at 5 years were overall survival 71% (95% confidence interval (CI) 66–75), local recurrence 7% (95% CI 5–10) and distant recurrence 18% (95% CI 14–22). Patients diagnosed with local recurrence died faster than patients diagnosed with either distant recurrence or no recurrence, and this was particularly obvious for younger patients (local hazard ratio (HR) 54, 95% CI 12–253 and distant HR19, 95% CI 4–80). Local recurrence that developed early following surgery also had worse survival outcomes. Conclusions: Within this cohort of rectal cancer patients, the early development of local recurrence was the single most important indicator of a reduced survival, and carried a worse prognosis than the development of distant metastases alone.
This is the accepted version of the following article: Platell, Cameron and Spilsbury, Katrina. 2014. Influence of local recurrence on survival in patients with rectal cancer. ANZ Journal of Surgery. 84 (1-2): pp. 85-90, which has been published in final form at http://doi.org/10.1111/ans.12214
Showing items related by title, author, creator and subject.
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic diseaseChan, Arlene; Morey, A.; Brown, B.; Hastrich, D.; Willsher, P.; Ingram, D. (2012)Background: Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in ...
Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment responseMcCoy, M.; Hemmings, C.; Anyaegbu, C.; Austin, S.; Lee-Pullen, T.; Miller, T.; Bulsara, M.; Zeps, Nikolajs; Nowak, A.; Lake, R.; Platell, C. (2017)Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors ...
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMartin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; Harvey, V.; Tomek, R.; Robert, N.; Gore, I.; Smith, J.; Masuda, N.; Di Sean Kendall, S.; Harker, W.; Petrakova, K.; Guerrero Zotano, A.; Simon, A.; Konstantinovic, Z.; Iannotti, N.; Tassone, P.; Rodriguez, G.; Jáñez Martinez, N.; Crespo Massieu, C.; Smickoska, S.; Somali, I.; Yilmaz, U.; Alonso, M.; Rosales, A.; Cold, S.; Knoop, A.; Patt, D.; Hellerstedt, B.; Morales Murillo, S.; Mayer, I.; Means-Powell, J.; Hui, R.; Senecal, F.; De Boer, R.; Shen, Z.; Luczak, A.; Chui, J.; Tsang, J.; Lang, I.; Rai, Y.; Hozumi, Y.; Ten Tije, A.; Bhandari, M.; Osborne, C.; Ohtani, S.; Higaki, K.; Watanabe, K.; Taguchi, K.; Takahashi, M.; Filipovic, S.; Hansen, V.; Rao, V.; Gupta, M.; Petrov, P.; Coudert, B.; Vojnovic, Z.; Polya, Z.; Miyaki, T.; Yamamoto, N.; Brincat, S.; Lesniewski-Kmak, K.; Chmielowska, E.; Birhiray, R.; Citron, M.; Papish, S.; Berry, W.; Langkjer, S. (2017)© 2017 Elsevier Ltd Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant ...